Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/7840E0F25AA1CBF8FA046D195C1320A848AA5FF27AEB15FB947D2C41DF23F915257653B4AF748561D91FB403F86029BFhttp://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/7840E0F25AA1CBF8FA046D195C1320A848AA5FF27AEB15FB947D2C41DF23F915257653B4AF748561D91FB403F86029BFhttp://www.w3.org/2000/01/rdf-schema#comment"Translational initiation pathway inhibition could be of clinical utility in male breast cancer patients overexpressing eIF4E and eIF5. With mTOR inhibitors that target this pathway now in the clinic these biomarkers may represent new targets for therapeutic intervention although further independent validation is required"xsd:string
http://purl.uniprot.org/uniprot/#_BEF9392E5026813D9E44AA34F62F9F3F3FA5468BA88042E8E00393A6287350027783E16787D5E1CE52C74CEBCF19E19Chttp://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/7840E0F25AA1CBF8FA046D195C1320A848AA5FF27AEB15FB947D2C41DF23F915257653B4AF748561D91FB403F86029BF
http://purl.uniprot.org/uniprot/Q6IBU0http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/7840E0F25AA1CBF8FA046D195C1320A848AA5FF27AEB15FB947D2C41DF23F915257653B4AF748561D91FB403F86029BF
http://purl.uniprot.org/uniprot/#_Q6IBU0-mappedCitation-27986751http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/7840E0F25AA1CBF8FA046D195C1320A848AA5FF27AEB15FB947D2C41DF23F915257653B4AF748561D91FB403F86029BF